SCHEMBL306061

SCHEMBL306061

CCCC(C)(C)[CH]CC(C)CCC(C)C

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.31
CYP3A4 P08684 1/20 0.31
ALOX15 P16050 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10412582 0.84 CA1 (0.31) MEN1CYP3A4ALOX15KMT2A
SCHEMBL5069895 0.81
SCHEMBL4456323 0.77
SCHEMBL5963338 0.69 TSHR (0.34)
SCHEMBL11070990 0.67 TSHR (0.40)
SCHEMBL19142935 0.65 MEN1 (0.32) MEN1CYP3A4ALOX15KMT2A
SCHEMBL4619172 0.65
SCHEMBL5266333 0.64
SCHEMBL29145068 0.64 MEN1 (0.32) MEN1CYP3A4ALOX15KMT2A
SCHEMBL9532807 0.63 LMNA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10551345-B2 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2020-02-04 US disclosed
US-20170356877-A1 POLY AND COPOLY(N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLIED BIOSYSTEMS, LLC (US) 2017-12-14 US disclosed
US-9671367-B2 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2017-06-06 US disclosed
EP-1814854-B1 CATIONIC CERAMIDES, AND ANALOGS THEREOF, AND THEIR USE FOR PREVENTING OR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2015-02-25 EP disclosed
US-20140209461-A1 Poly and Copoly(N-vinylamide)s and Their Use In Capillary Electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2014-07-31 US disclosed
EP-1660597-B1 COPOLYMER SURFACTANTS MOORE BENJAMIN & CO (US) 2014-03-05 EP disclosed
US-8329807-B2 Latex paint film resistant to adverse effects of water, and compositions and methods for making same COLUMBIA INSURANCE COMPANY (US) 2012-12-11 US disclosed
US-8093393-B2 Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2012-01-10 US disclosed
US-20110071099-A1 Cationic Ceramides, And Analogs Thereof, And Their Use For Preventing Or Treating Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2011-03-24 US disclosed
US-20100051461-A1 Poly and Copolyn(N-Vinylamide)s and their use in Capillary Electrophoresis Life Technologies Corporation (US) 2010-03-04 US disclosed
WO-2005035500-A2 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2005-04-21 WO disclosed
US-6864261-B2 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2005-03-08 US disclosed
WO-2005019353-A2 COPOLYMER SURFACTANTS COLUMBIA INSURANCE COMPANY (US) 2005-03-03 WO disclosed
US-20050039635-A1 Copolymer surfactants BENJAMIN MOORE & CO. 2005-02-24 US disclosed
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides APPLIED BIOSYSTEMS, LLC 2005-02-03 US disclosed
WO-2004104054-A1 POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLERA CORPORATION (US) 2004-12-02 WO disclosed
US-20040127501-A1 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2004-07-01 US disclosed
WO-2004029044-A1 PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS EURO-CELTIQUE, S.A. (LU) 2004-04-08 WO disclosed
US-20040053914-A1 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. 2004-03-18 US disclosed
WO-2003093236-A1 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR EURO-CELTIQUE, S.A. (LU) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053914-A1 Therapeutic agents useful for treating pain SMN1; SMN2, OPRM1, PSEN1 MEN1 1955/4885CYP3A4 4358/4885ALOX15 587/4885
US-20110071099-A1 Cationic Ceramides, And Analogs Thereof, And Their Use For Preventing Or Treating Cancer CERS2, CERT1, SGMS1 MEN1 2416/4885CYP3A4 4531/4885ALOX15 1219/4885
US-20040127501-A1 Therapeutic agents useful for treating pain CACNA1A, GRIN2A, HTT MEN1 2295/4885CYP3A4 3931/4885ALOX15 935/4885
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides POLI, PCNA, POLL MEN1 2730/4885CYP3A4 3975/4885ALOX15 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.